An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

Dec 3, 2019Expert opinion on pharmacotherapy

Liraglutide’s effectiveness and safety for treating obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake.

Liraglutide is approved for the treatment of obesity in patients with and without type 2 diabetes.
The drug's effects on weight loss are independent of its glucose-lowering properties.
Common adverse effects of liraglutide are generally not serious.
Liraglutide may reduce cardiovascular events in patients with type 2 diabetes.
The cost and requirement for daily injections could limit its use for obesity management.
Newer GLP-1 receptor agonists, like semaglutide, may offer advantages over liraglutide.

AI simplified

: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervention should be the first line of management for obesity but additional pharmacotherapy is often required and bariatric surgery is appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects. Like most of the other medications currently available for obesity, liraglutide has some common adverse effects, although generally not serious ones. Liraglutide has additional benefits in reducing cardiovascular events in patients with T2DM but the cost and the need for daily injections may limit its use in obesity. Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide. Introduction Areas covered Expert opinion

Full Text

Full text is available at the source.

View full text ↗

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief